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A heteroplasmic point mutation (transition A-to-G at nucleotide position 3,243 in the mitochondrial tRNALe”(““a) gene) is found in a family 
suffering from a syndrome with diabetes, deafness and cardiomyopathy as the predominant clinical features. 
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1. INTRODUCTION 
Although diabetes has, without doubt, a genetic 
background, extensive research worldwide has until 
now been unable to define the genetic lesions and the 
mode of inheritance of the different forms of the disease. 
In our attempts to clear up the genetics of diabetes we 
are confronted with a number of obstacles uch as dif- 
ferences and uncertainties in the definition of affected 
individuals, variabilities in the age of onset and the 
expression of the disease, its high but different preva- 
lences in different populations, varying rates of concor- 
dance in monozygotic twins, etc. [l]. Therefore, the clas- 
sification of diabetes is less genetic but largely descrip- 
tive. Diabetes is currently divided into two idiopathic 
forms, one insulin-dependent ( ype l), one insulin-inde- 
pendent (type 2) and those forms which are associated 
with several syndromes [l]. Recent observations de- 
monstrating that defects in the mitochondrial DNA 
(mtDNA) can lead not only to mitochondrial encepha- 
lomyopathies [2] but also to diabetes [3-51 have opened 
a new dimension for the respective genetic research. One 
of the mtDNA mutations associated with mitochondrial 
disorders is a A/G transition at nt position 3,243 within 
the tRNALeuu’UR) gene which is found in about 90% of 
patients with MELAS [6-91. Here we describe a family 
which carries this mutation but shows different pheno- 
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The pedigree is shown in Fig. 1. Both females in the second gener- 
ation (II,; II,) had type 2 diabetes and mild sensorineural hearing loss. 
The affected male in the third generation (III,) developed eafness at 
the age of 22, insulin-dependent diabetes at 26 years, hemiparesis at 
41 years. He also suffered from a massive hypertrophic ardiomyopa- 
thy and had myocardial infarction at the age of 39. His brother (1113 
had progredient dementia beginning at the age of 10 years. At the age 
of 20 he developed an insulin-dependent diabetes; at 30 and 32 years 
he had two episodes with hemianopsia, hemiparesis, motor aphasia, 
ataxia, frontal headache and two generalized tonic-clonic seizures 
(grand-mal). During his last years he developed a massive hypertro- 
phic cardiomyopathy. Laboratory investigations revealed elevated 
lactate levels during rest and mild exercise as well as raised blood sugar 
values. Ragged red fibers and a mosaic pattern of single cytochrome 
c oxidase negative fibers were found in a muscle biopsy at the age of 
32. He died at the age of 42 from cardiac failure. The sister (III,) 
showed normal development until the age of 36 years, when she had 
one single attack of headache and vomiting. During this time mild 
hearing loss and glucose imbalance treatable with diet was diagnosed. 
Islet cell antibodies and insulin antibodies were negative. Her son (IV; 
1978) is symptomless until now (15 years). 
2.2. Method 
DNA was extracted from EDTA-blood and other tissues as de- 
scribed [lo]. To detect possible deletions, the mtDNA was subjected 
to digestion with the endonucleases BarnHI and PvuII, followed by 
Southern blotting. For the 3,243 mutation, the relevant region of 
mtDNA was amplified by PCR using the primer sequences 3,153- 
3,172 (upstream) and 3,501-3,474 (downstream) according to the 
Cambridge sequence. The 349 bp product was then digested with 
ApaI. The A/G transition at nt 3,243 creates a new restriction site for 
ApaI leading to two fragments of 255 bp and 94 bp in length. To detect 
small amounts of mutated mtDNA in the presence of an excess of 
wild-type mtDNA, we performed allele specific mismatch priming 
using an upstream primer (nt 3,2243,243) which carried the mutation 
(G instead of A) at nt 3,243 and a mismatch (G instead of C) at nt 3,240 
on one site and the downstream primer 3,551-3,531 on the other site. 
The expected fragment was 328 bp long. 
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Fig. 1. Pedigree. Fully filled symbols = diabetes mellitus, deafness, 
cardiomyopathy and various neurological symptoms; dotted sym- 
bols = diabetes and deafness without other symptoms. 
3. RESULTS 
Restriction analysis and Southern blotting failed to 
detect any deletion of native mtDNA extracted from 
blood. PCR amplification and digestion by ApaI yielded 
the point mutation at nt 3,243 in all samples from the 
family members of the third and fourth generation in a 
heteroplasmic form (Fig. 2). In the blood samples from 
both parents in the second generation, however, the 
respective PCR products were neither digested by ApaI 
(Fig. 2) nor by Hue111 (data not shown). The use of the 
allele specific mismatch primer produced the expected 
fragments in the blood samples from the subjects III,, 
III,, IV, and a very faint, hardly visible band in that 
from the mother (II,), while in the father’s sample (II,) 
no amplified fragment was detectable (Fig. 3). 
4. DISCUSSION 
The question of whether the mtDNA is involved in 
the pathogenesis of diabetes was recently discussed in 
detail [l 11. In the meantime several publications have 
confirmed the hypothetical assumption that some forms 
of diabetes are associated with or even caused by defects 
of the mtDNA [4-61. Our observation emphasizes the 
relation between diabetes and a specific A/G transition 
mutation at nt 3,243 within the tRNALe”(UUR) gene [4,5] 
which has most commonly been observed in MELAS 
patients [6-g]. Although all family members along the 
matrilineage carry the 3,243 mutation their clinical fea- 
tures are different. Diabetes in its insulin-dependent and 
in its insulin-independent forms as well as hearing loss 
are the predominant clinical features in all family mem- 
bers with the exception of the young healthy boy in the 
last generation. MELAS typical symptoms such as 
strokes, seizures, hemiparesis, dementia, muscle weak- 
ness as well as severe cardiomyopathy are found only 
in the two brothers in the third generation and not in 
the others. Since the 3,243 mutation occurs in a highly 
conserved portion of the tRNALe”(UUR) gene and has, so 
far, not been observed in healthy subjects [2,6-g], it is 




Fig. 2. PCR amplified mtDNA fragments after cleavage with Apa 
visualized on ethidiuin bromide agarose gel. In the presence of the A/G 
transition at 3,243 ApuI cuts the 349 bp fragment into two smaller 
fragments 255 and 94 bp in length. Numbers represent pedigree mem- 
bers in Fig. 1. 
seems to be due to differential expression of the mutant 
genotype in different tissues with different thresholds. 
Measurements in blood cells might not reflect the situa- 
tion in the affected tissues. For example, in blood cells 
of the diabetic grandmother in the second generation 
(II& restriction analysis using ApuI digested PCR frag- 
ments does not provide any evidence for the 3,243 mu- 
tation. Furthermore, allele specific mismatch priming 
yields only a very faint band in the grandmother’s 
blood. In contrast, the healthy boy (15 years) in the 
fourth generation carries a relatively high amount of 
mutant mtDNA in his blood cells. Thus it seems likely 
that other epigenic factors, mitochondrial or nuclear in 
origin, influence penetrance and expression of the syn- 
drome. Recent cell culture studies with cell lines con- 
taining in heteroplasmic form the 3,243 tRNALe”(UUR) 
mutation, that were constructed by introducing mutant 
mtDNA into mtDNA-depleted cells, have demon- 
strated a marked replicative advantage of mutant over 
wild-type mtDNA [12]. The reason for this phenome- 
non, which can result in a rapid genetic drift towards 
high degree of mutant mtDNA, is unclear so far. 
Fig. 3. PCR fragments amplified by use of allele specific mismatch 
priming. Numbers represent pedigree members in Fig. 1. C, controls; 
MELAS, two index patients from another family with typical MELAS 
syndrome but without diabetes. 
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MtDNA deletions [3] and point mutations [4,5] are not 
only found in maternally transmitted familial diabetes, 
but also in occasional patients as well as in single pedi- 
gree members. suffering from both mitochondrial 
encephalomyopathy and diabetes. In none of the re- 
ported cases is diabetes the only symptom; there is al- 
ways an association with other clinical symptoms such 
as deafness, ataxia, renal tubulopathy, etc., which are 
usually not combined with diabetes [l 1 ,131. Thus it 
seems unlikely that those forms of diabetes which are 
associated with mtDNA mutations belong to the classi- 
cal idiopathic type 1 or type 2 diabetes. They may rep- 
resent subclassifications which are part of syndromic 
disorders. This assumption is supported by the fact that 
even in insulin-dependent subjects with mtDNA muta- 
tions testing for islet cell antibodies has revealed nega- 
tive results in any case [5]. 
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